Clinical trials: Helminthiasis
Filariasis
Relative Bioavailability Study of Emodepside IR-tablets and Solution
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov…
- Trial name
- NCT03383523
- Testing
- Emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Schistosomiasis, Schistosomiasis Mansoni
Praziquantel in Children Under Age 4
The overall goals of this proposal are to conduct a trial to address the significant gaps with respect to our understanding of best approaches to treatment of children ages 1-4 with intestinal schistosomiasis.
- Conditions
- Schistosomiasis, Schistosomiasis Mansoni, Schistosoma Japonicum Infection
- Trial name
- PIP (NCT03640377)
- Testing
- Praziquantel
- Where
- 2 sites in Uganda, United Kingdom
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Rhode Island Hospital
Schistosomiasis, Health Education
Health Education Model Led by Community Health Volunteers.
The goal of this intervention study is to investigate the level of knowledge, attitudes, and behaviors of students on schistosomiasis in Pemba Island.
- Trial name
- NCT06312462
- Testing
- health education
- Where
- Tanzania
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Pemba Ministry of Health Zanzibar
Filariasis
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
- Trial name
- NCT03383614
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Hookworm Infections
Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
The rational of this study is to provide evidence on the safety and efficacy of a new chewable tablet of mebendazole compared to the standard tablet in preschool- and school-aged children infected with hookworm.
- Trial name
- CHEW_MEB_PEMBA (NCT03995680)
- Testing
- Mebendazole
- Where
- Tanzania
- Volunteers
- 397 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Hookworm Infections
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.
- Trial name
- NCT03172975
- Testing
- Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Malaria, Lymphatic Filariasis
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in…
- Trial name
- RIMDAMAL (NCT02509481)
- Testing
- Ivermectin, Albendazole
- Where
- 2 sites in United States, Burkina Faso
- Volunteers
- 2,712 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant
This study is designed to evaluate the safety, reactogenicity, and immunogenicity of Na-GST-1 adsorbed to Alhydrogel® with or without two different dose concentrations of a novel adjuvant, GLA-AF (1 µg or 5 μg) among healthy…
- Trial name
- NCT01385189
- Testing
- 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Lymphatic Filariasis
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi
Albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such programmes is very high and has proven to be a major…
- Trial name
- FED (NCT01213576)
- Testing
- Albendazole 400mg and ivermectin 200mcg/kg, Albendazole and ivermectin, albendazole 800mg and ivermectin 400mcg/kg bi-annually
- Where
- Malawi
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Helminthiasis, Filariasis
Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Over 1.5 billion people are infected with soil-transmitted helminths (STH). Global STH guidelines recommend MDA (mass drug administration) of albendazole or mebendazole to targeted populations, including pre-school age children…
- Trial name
- NCT03014167
- Testing
- Albendazole
- Where
- 3 sites in Benin, India and 1 more
- Volunteers
- 357,716 people, healthy volunteers welcome
- Sponsor
- University of Washington
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity Study of Na-GST-1 With or Without CpG
Na-GST-1 is a protein expressed during the adult stage of the hookworm life cycle that is thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source.
- Trial name
- NCT02143518
- Testing
- Na-GST-1/Alhydrogel®, CpG 10104
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Helminthiasis
Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population
The purpose of the study is to compare the pharmacokinetic profiles of two Albendazole tablet formulations manufactured under the different granulation processes in healthy Chinese adult males.
- Trial name
- NCT01755637
- Testing
- Albendazole
- Where
- 2 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neurocysticercosis
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
The objectives of the Phase I study are to evaluate the safety and tolerance of increasing single oral doses of oxfendazole in healthy volunteers.The secondary objectives assess the pharmacokinetic profile of oxfendazole and…
- Trial name
- NCT02234570
- Testing
- Oxfendazole
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Schistosomiasis
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
This is a Phase 1, open-label, dose-escalation clinical trial to evaluate the safety, reactogenicity, and immunogenicity of the Sm-p80+GLA-SE vaccine candidate in healthy adults between 18 and 55 years of age.
- Trial name
- NCT05292391
- Testing
- Sm-p80, Sm-p80 + GLA-SE
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hookworm Infection
Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset…
- Trial name
- NCT00939198
- Testing
- Na-ASP-2 Skin Test Reagent
- Where
- Brazil
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Healthy Volunteers
First in Man Clinical Trial of Emodepside (BAY 44-4400)
This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers.
- Trial name
- NCT02661178
- Testing
- emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schistosomiasis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
The goal of this phase 1b, multicenter, randomized, placebo-controlled, observer-blinded, dose-escalation study is to assess the safety, tolerability, and immunogenicity of a three-dose regimen, spaced four weeks apart, given…
- Trial name
- NCT05762393
- Testing
- rSm-p80 + GLA-SE
- Where
- 2 sites in Burkina Faso, Madagascar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Lymphatic Filariasis
Moxidectin for LF, Cote d'Ivoire (DOLF)
The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
- Trial name
- NCT04410406
- Testing
- Ivermectin, Diethylcarbamazine, Albendazole
- Where
- Côte d’Ivoire
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariasis
Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
According to the World Health Organization, lymphatic filariasis, a mosquito-borne parasitic disease, is the second leading cause of disability worldwide.
- Trial name
- NCT01629771
- Where
- 2 sites in United States, India
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Northwestern University